Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 8/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755232 | 0.93 | ADH5 (0.37) | ADH5CYP19A1ESR1ESR2ALDH1A1 | |
| SCHEMBL5752911 | 0.80 | KMT2A (0.41) | ALDH1A1PTPN1 | |
| SCHEMBL29572389 | 0.80 | KMT2A (0.41) | ALDH1A1PTPN1 | |
| SCHEMBL5755297 | 0.78 | IDO1 (0.42) | ADH5ALDH1A1 | |
| SCHEMBL5754006 | 0.78 | IDO1 (0.42) | ALDH1A1CD38 | |
| SCHEMBL5791221 | 0.78 | GAA (0.36) | ALDH1A1PTPN1 | |
| SCHEMBL7950741 | 0.77 | TRPV1 (0.41) | ALDH1A1 | |
| SCHEMBL27446635 | 0.75 | CYP19A1 (0.38) | ADH5CYP19A1ESR1ESR2ALDH1A1 | |
| SCHEMBL5753883 | 0.74 | KMT2A (0.41) | ALDH1A1PTPN1 | |
| SCHEMBL7957026 | 0.72 | P2RX1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | claimed |
| EP-0915856-A4 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0915856-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998004135-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |